JNJ Sells Orthopedics Unit as MedTech Portfolio Gets Reset

Johnson & Johnson (JNJ) is reportedly in talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management. The potential transaction would involve J&J's orthopedics franchise within its MedTech segment, including DePuy Synthes assets.

A sale of DePuy Synthes to Apollo would represent a significant reshaping of Johnson & Johnson's medical devices portfolio and come against a broader repositioning of the company. This possible reshaping is one angle on the theme, and there are other stocks exposed to it too.

The reported DePuy Synthes sale discussions with Apollo could free capital and management time for areas like cardiovascular technology and robotics that analysts already focus on. It effectively swaps breadth in joint and spine implants for a tighter focus on higher priority MedTech bets.